Active Ingredient History
Nicardipine is a potent calcium channel blockader with marked vasodilator action used to treat high blood pressure and angina. By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, nicardipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Angina, Stable (approved 1988)
Acute Coronary Syndrome (Phase 4)
Anesthesia (Phase 4)
Aortic Aneurysm, Thoracic (Phase 2)
Brain Neoplasms (Phase 1)
Cerebral Hemorrhage (Phase 3)
Coronary Artery Disease (Phase 4)
Coronary Vasospasm (Early Phase 1)
Hypertension ()
Ischemic Stroke (Phase 4)
Malocclusion, Angle Class III (Phase 4)
Mandibular Diseases (Phase 4)
Organs at Risk (Phase 4)
Orthognathic Surgery (Phase 4)
Pain (Early Phase 1)
Pre-Eclampsia (Phase 3)
Spasm (Phase 3)
Spinal Stenosis (Phase 4)
Stroke (Phase 2)
Subarachnoid Hemorrhage (Phase 2)
Vascular Diseases (Phase 2)
Vasospasm, Intracranial (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue